ESMO Events 2024

Meetingsopens in new tab/window | ESMOopens in new tab/window

Welcome to our ESMO Virtual Congress site where we showcase the very best from ESMO's flagship portfolio.

ESMO Gastrointestinal Cancers Congress 2024opens in new tab/window

Brought to you by the European Society for Medical Oncology (ESMO), the congress will be the place to present impactful new data in GI oncology. The scientific sessions will be complemented with high quality educational sessions and excellent networking opportunities.

In recent years we have seen remarkable progress in the treatment options available for patients with GI cancers and ESMO is committed to ensuring that there is a clear roadmap to help facilitate the implementation of new practice changing discoveries in the clinic for the benefit of all patients with GI cancers and whose wellbeing is our primary concern.

The ESMO Gastrointestinal Cancers Congress will provide global visibility for original clinical and translational research.

Below a collection of papers recently published in ESMO’s premier journals carefully selected to reflect the themes of the meeting.

Annals of Oncology

• ●

  Proofreading the way: immune checkpoint inhibitors in polymerase ε/polymerase δ (POLE/POLD1)-altered colorectal canceropens in new tab/window M. Cecchini, R. Sundar

• ●

  Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal canceropens in new tab/window M. Ambrosini †, B. Rousseau †, P. Manca, O. Artz, A. Marabelle, T. André, G. Maddalena, G. Mazzoli, R. Intini, R. Cohen, A. Cercek, N.H. Segal, L. Saltz, A.M. Varghese, R. Yaeger, M. Nusrat, Z. Goldberg, G.Y. Ku, I. El Dika, O. Margalit, A. Grinshpun, P. Murtaza Kasi, R. Schilsky, A. Lutfi, E. Shacham-Shmueli, M. Khan Afghan, L. Weiss, C.B. Westphalen, V. Conca, B. Decker, G. Randon, E. Elez, M. Fakih, A.B. Schrock, C. Cremolini, P. Jayachandran, M.J. Overman, S. Lonardi, F. Pietrantonio

• ●

  Genome-wide association studies and Mendelian randomization analyses provide insights into the causes of early-onset colorectal canceropens in new tab/window R.S. Laskar, C. Qu, J.R. Huyghe, T. Harrison, R.B. Hayes, Y. Cao, P.T. Campbell, R. Steinfelder, F.R. Talukdar, H. Brenner, S. Ogino, S. Brendt, D.T. Bishop, D.D. Buchanan, A.T. Chan, M. Cotterchio, S.B. Gruber, A. Gsur, B. van Guelpen, M.A. Jenkins, T.O. Keku, B.M. Lynch, L. Le Marchand, R.M. Martin, K. McCarthy, V. Moreno, R. Pearlman, M. Song, K.K. Tsilidis, P. Vodička, M.O. Woods, K. Wu, L. Hsu, M.J. Gunter †, U. Peters †, N. Murphy †, on behalf of theColorectal Transdisciplinary (CORECT) Study, the Colon Cancer Family Registry (CCFR), Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO)

• ●

  Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040☆opens in new tab/window I. Melero, T. Yau, Y.-K. Kang, T.-Y. Kim, A. Santoro, B. Sangro, M. Kudo, M.-M. Hou, A. Matilla, F. Tovoli, J. Knox, A.R. He, B. El-Rayes, M. Acosta-Rivera, H.Y. Lim, S. Soleymani, J. Yao, J. Neely, M. Tschaika, C. Hsu, A.B. El-Khoueiry

ESMO Open

• ●

  Sunitinib for the treatment of metastatic gastrointestinal stromal tumors: the effect of TDM-guided dose optimization on clinical outcomesopens in new tab/window E.L. Giraud †, K. Westerdijk †, M.B.A. van der Kleij, N.A.D. Guchelaar, M. Meertens, R.F. Bleckman, A. Rieborn, M. Mohammadi, E. Roets, R.H.J. Mathijssen, A.D.R. Huitema, S.L.W. Koolen, H. Gelderblom, D.J.A.R. Moes, A.K.L. Reyners, D.J. Touw, P. Keizer-Heldens, A.W. Oosten, W.T.A. van der Graaf, N. Steeghs, N.P. van Erp, I.M.E. Desar, on behalf of theDutch Pharmacology Oncology Group (DPOG)

• ●

  An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202☆opens in new tab/window

  A. Vogel, V. Sahai, A. Hollebecque, G.M. Vaccaro, D. Melisi, R.M. Al Rajabi, A.S. Paulson, M.J. Borad, D. Gallinson, A.G. Murphy, D.-Y. Oh, E. Dotan, D.V. Catenacci, E. Van Cutsem, C.F. Lihou, H. Zhen, M.L. Veronese, G.K. Abou-Alfa

• ●

  Anaemia is independently associated with mortality in patients with hepatocellular carcinomaopens in new tab/window T. Meischl, L. Balcar, Y.-R. Park, L. Bucher, P. Meier, Y. Suhr, K. Pomej, M. Mandorfer, T. Reiberger, M. Trauner, B. Scheiner, M. Pinter

ESMO Gastrointestinal Oncology

• ●

  Feasibility of stereotactic radiotherapy with pembrolizumab in patients with deficient mismatch repair/microsatellite unstable metastatic colorectal canceropens in new tab/window A. Gandini, V. Martelli, L. Belgioia, S. Puglisi, M. Cremante, V. Murianni, A. Damassi, C. Pirrone, F. Catalano, M. Grassi, L. Trevisan, S. Vagge, V. Andretta, S. Mammoliti, D. Comandini, G. Fornarini, A. Pessino, A. Pastorino, S. Sciallero, A. Puccini, A.F. Sobrero

• ●

  Safety and efficacy of first-line nivolumab plus chemotherapy for HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: real-world data analysisopens in new tab/window

  K. Shimozaki, K. Fukuda, A. Ooki, I. Nakayama, K. Yoshino, M. Tamba, S. Udagawa, S. Fukuoka, H. Osumi, T. Wakatsuki, D. Takahari, E. Shinozaki, M. Ogura, K. Chin, K. Yamaguchi

• ●

  Consistency of a clinical decision support system with molecular tumour board recommendations for tumour sequencing-guided treatment of pancreatic canceropens in new tab/window

  M. Kordes †, L. Malgerud †, ‡, J.-E. Frödin, J. Yachnin, C. Fernandez Moro, S. Ghazi, R. Pozzi Mucelli, N. Kartalis, P. Ghorbani, M. Del Chiaro §, V. Wirta, M. Björnstedt, M.G. Liljefors ¶, J.-M. Löhr ¶

ESMO Real World Data and Digital Oncology

• ●

  Toward optimizing patient selection for EGFR antibody therapies in metastatic colorectal cancer: outcomes and resistance features in real-world dataopens in new tab/window M.J. Emmett †, J.C.F. Quintanilha †, R.P. Graf, G. Li, H. Tukachinsky, A.B. Schrock, S. Morley, V.A. Fisher, G.R. Oxnard, C.H. Lieu, P.A. Myer, S.J. Klempner

• ●

  Health-related quality of life in patients with gastrointestinal stromal tumor: data from a real-world cohort compared with a normative populationopens in new tab/window D. van de Wal, D. den Hollander, I.M.E. Desar, H. Gelderblom, A.W. Oosten, A.K.L. Reyners, N. Steeghs, W.T.A. van der Graaf †, O. Husson †

• ●

  Changes in survival of >3800 patients with metastatic colorectal cancer in Germany: results from a 16-year prospective longitudinal real-world data analysisopens in new tab/window

  N. Marschner †, T. Seufferlein †, K. Potthoff †, M.-O. Zahn, J. Uhlig, S. Dörfel, A. Karcher, A. Sauer, C. Maintz, S. Fruehauf, U. Hutzschenreuter, S. Tech, M. Grafetstätter, L. Kruggel, M. Jänicke

ESMO affiliated journals

• ●

  Non-operative management after immune checkpoint inhibitors for early-stage, dMMR/MSI-H gastrointestinal cancersopens in new tab/window Roberta Fazio, Alessandro Audisio, Valentina Daprà, Chiara Conti, Nada Benhima, Fatima-Zahara Abbassi, Irene Assaf, Alain Hendlisz, Francesco Sclafani

• ●

  Oncological outcomes of local excision versus radical surgery for early rectal cancer in the context of staging and surveillance: A systematic review and meta-analysisopens in new tab/window

  Michael G. Fadel, Mosab Ahmed, Annabel Shaw, Matyas Fehervari, Christos Kontovounisios, Gina Brown

ESMO's Journal Portfolio

While diverse in nature and in content, these journals offer ESMO members and the oncology community a highly visible platform to publish important scientific studies, and a highly credible source for educational updates. Elsevier is the proud publisher of Annals of Oncology, Immuno-Oncology and Technology (IOTECH), ESMO Open, ESMO Gastrointestinal Oncology, ESMO Real World Data and Digital Oncology, and ESMO Affiliated Journals The Breast, Lung Cancer, Cancer Treatment Reviews and Clinical Lymphoma Myeloma and Leukemia.